Evidence map›Paper›PMID 28474573›Full record

ArticleOncology research2018

Corilagin Induces High Levels of Apoptosis in the Temozolomide-Resistant T98G Glioma Cell Line.

Roberta Milani, Eleonora Brognara, Enrica Fabbri, Alessia Finotti, Monica Borgatti, Ilaria Lampronti, Giovanni Marzaro, Adriana Chilin, Kenneth Ka-Ho Lee, Stanton Hon-Lung Kok and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Oncology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Roberta MilaniDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Eleonora BrognaraDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Enrica FabbriDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Alessia FinottiDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Monica BorgattiDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Ilaria LamprontiDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Giovanni MarzaroDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Adriana ChilinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Kenneth Ka-Ho LeeSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, P.R. China.
Stanton Hon-Lung KokSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, P.R. China.
Chung-Hin ChuiDepartment of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, P.R. China.
Roberto GambariDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
University of Ferrara · ITUniversity of Padua · ITChinese University of Hong Kong · CNPrince of Wales Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM), a malignant tumor of the central nervous system, has a high mortality rate. No curative treatment is presently available, and the most commonly used chemotherapeutic drug, the alkylating agent temozolomide (TMZ), is only able to increase life expectancy and is often associated with drug resistance. Therefore, an urgent need does exist for novel drugs aimed at treating gliomas. In the present study, we obtained three major results using corilagin: (a) demonstrated that it inhibits the growth of U251 glioma cells through activation of the apoptotic pathway; (b) demonstrated that it is also active on TMZ-resistant T98G glioma cells; and (c) demonstrated that when used in combination with TMZ on T98G glioma cells, a higher level of proapototic and antiproliferative effects is observed. Our study indicates that corilagin should be investigated in more detail to determine whether it can be developed as a potential therapeutic agent. In addition, our results suggest that corilagin could be used in combination with low doses of other standard anticancer chemotherapeutic drugs against gliomas (such as TMZ) with the aim of obtaining enhanced anticancer effects.

Identifiers

PMID28474573
PMCPMC7844640
OpenAlexW2610318517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.